幽门螺杆菌根除失败后阿莫西林耐药性增强。
Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.
机构信息
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
出版信息
Antimicrob Agents Chemother. 2011 Jun;55(6):3012-4. doi: 10.1128/AAC.00188-11. Epub 2011 Apr 12.
Abstract
A high rate of resistance (49.5 to 72.7%) to amoxicillin (AMX) was observed in Helicobacter pylori after two or three unsuccessful eradication attempts. Unsuccessful eradication regimens significantly increase resistance to not only clarithromycin (CLR) and metronidazole (MNZ) but also AMX.
摘要
在两次或三次根除尝试失败后，观察到幽门螺杆菌对阿莫西林（AMX）的耐药率很高（49.5 至 72.7%）。不成功的根除方案不仅显著增加了克拉霉素（CLR）和甲硝唑（MNZ）的耐药性，也增加了 AMX 的耐药性。
相似文献
1
Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.幽门螺杆菌根除失败后阿莫西林耐药性增强。
Antimicrob Agents Chemother. 2011 Jun;55(6):3012-4. doi: 10.1128/AAC.00188-11. Epub 2011 Apr 12.
2
Treatment regimens for Helicobacter pylori infection in children: is in vitro susceptibility testing helpful?儿童幽门螺杆菌感染的治疗方案：体外药敏试验有帮助吗？
J Pediatr Gastroenterol Nutr. 2005 May;40(5):571-4. doi: 10.1097/01.mpg.0000155567.71902.75.
3
Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan.克拉霉素与甲硝唑作为一线根除幽门螺杆菌治疗方案的比较：日本一项多中心、前瞻性、随机对照研究
J Clin Gastroenterol. 2015 Jul;49(6):468-71. doi: 10.1097/MCG.0000000000000165.
4
10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.基于司他夫定的三线补救治疗的幽门螺杆菌根除率的 10 年趋势。
Digestion. 2020;101(5):644-650. doi: 10.1159/000501610. Epub 2019 Aug 6.
5
Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for infection.铋剂四联疗法中阿莫西林或四环素作为一线治疗 感染。
Gut Microbes. 2020 Sep 2;11(5):1314-1323. doi: 10.1080/19490976.2020.1754118. Epub 2020 May 2.
6
High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents.巴西儿童和青少年的幽门螺杆菌对甲硝唑和克拉霉素的耐药率较高。
J Pediatr Gastroenterol Nutr. 2013 Jun;56(6):645-8. doi: 10.1097/MPG.0b013e31828b3669.
7
Antimicrobial-resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018-2020.日本的耐抗生素幽门螺杆菌：2018-2020 年全国监测报告。
Helicobacter. 2024 Jan-Feb;29(1):e13028. doi: 10.1111/hel.13028. Epub 2023 Oct 12.
8
Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.在西班牙北部，5 年内（2013-2017 年）幽门螺杆菌的抗菌药物耐药性及其与根除治疗的关系。
Helicobacter. 2019 Feb;24(1):e12557. doi: 10.1111/hel.12557. Epub 2018 Nov 20.
9
Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.在克拉霉素高耐药地区，采用埃索美拉唑、甲硝唑、阿莫西林和克拉霉素十天疗法的临床评估。
Helicobacter. 2013 Dec;18(6):459-67. doi: 10.1111/hel.12062. Epub 2013 May 29.
10
A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori.
Digestion. 2007;76(3-4):215-20. doi: 10.1159/000112649. Epub 2007 Dec 21.
引用本文的文献
1
Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.通过药敏试验和耐药分离株突变特征分析鉴定人胃内幽门螺杆菌异质性。
Sci Rep. 2024 May 27;14(1):12066. doi: 10.1038/s41598-024-62200-1.
2
Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Infections.抗生素耐药性的分子机制及感染的新型治疗策略
Trop Med Infect Dis. 2023 Mar 11;8(3):163. doi: 10.3390/tropicalmed8030163.
3
Clinical Implications of Antibiotic Resistance in Italy: A Review of the Literature.意大利抗生素耐药性的临床影响：文献综述
Antibiotics (Basel). 2022 Oct 21;11(10):1452. doi: 10.3390/antibiotics11101452.
4
Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.低剂量利福布汀为基础的 7 天三联疗法作为三线或更后线幽门螺杆菌根除方案的疗效和安全性。
Helicobacter. 2022 Aug;27(4):e12900. doi: 10.1111/hel.12900. Epub 2022 May 29.
5
Interplay between Amoxicillin Resistance and Osmotic Stress in Helicobacter pylori.阿莫西林耐药性与幽门螺杆菌渗透胁迫的相互作用。
J Bacteriol. 2022 May 17;204(5):e0004522. doi: 10.1128/jb.00045-22. Epub 2022 Apr 7.
6
Sitafloxacin for Third-Line Eradication: A Systematic Review.西他沙星用于三线根除治疗：一项系统评价
J Clin Med. 2021 Jun 20;10(12):2722. doi: 10.3390/jcm10122722.
7
Genetic and Transcriptomic Variations for Amoxicillin Resistance in under Cryopreservation.冷冻保存条件下阿莫西林耐药性的遗传和转录组变异
Pathogens. 2021 May 30;10(6):676. doi: 10.3390/pathogens10060676.
8
Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.幽门螺杆菌感染和抗生素耐药性 - 从生物学到临床意义。
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):613-629. doi: 10.1038/s41575-021-00449-x. Epub 2021 May 17.
9
Whole-Genome Sequencing and Comparative Genomics of Three Strains Isolated from the Stomach of a Patient with Adenocarcinoma.从一名腺癌患者胃部分离出的三株菌株的全基因组测序与比较基因组学
Pathogens. 2021 Mar 12;10(3):331. doi: 10.3390/pathogens10030331.
10
Eradication According to Sequencing-Based 23S Ribosomal RNA Point Mutation Associated with Clarithromycin Resistance.基于与克拉霉素耐药相关的23S核糖体RNA点突变测序的根除治疗
J Clin Med. 2019 Dec 25;9(1):54. doi: 10.3390/jcm9010054.
本文引用的文献
1
Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori.增强的细菌外排系统是幽门螺杆菌对甲硝唑耐药性发展的第一步。
Biochem Biophys Res Commun. 2011 Jan 14;404(2):656-60. doi: 10.1016/j.bbrc.2010.12.034. Epub 2010 Dec 11.
2
Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.外排泵对幽门螺杆菌克拉霉素耐药性的贡献。
J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S75-9. doi: 10.1111/j.1440-1746.2009.06220.x.
3
Helicobacter pylori eradication therapy.幽门螺杆菌根除治疗。
Future Microbiol. 2010 Apr;5(4):639-48. doi: 10.2217/fmb.10.25.
4
Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.基于喹诺酮的三线疗法根除幽门螺杆菌。
J Clin Biochem Nutr. 2009 Mar;44(2):119-24. doi: 10.3164/jcbn.08-220R. Epub 2009 Feb 28.
5
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.司帕沙星和加雷沙星可能克服携带gyrA基因突变的幽门螺杆菌的抗生素耐药性。
Antimicrob Agents Chemother. 2009 Apr;53(4):1720-1. doi: 10.1128/AAC.00049-09. Epub 2009 Feb 2.
6
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.基于加替沙星的三联疗法作为根除幽门螺杆菌的三线治疗方案。
J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S167-70. doi: 10.1111/j.1440-1746.2008.05407.x.
7
Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori.青霉素结合蛋白1、2和3的突变是幽门螺杆菌对阿莫西林耐药的原因。
J Antimicrob Chemother. 2008 May;61(5):995-8. doi: 10.1093/jac/dkn051. Epub 2008 Feb 14.
8
A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori.
Digestion. 2007;76(3-4):215-20. doi: 10.1159/000112649. Epub 2007 Dec 21.
9
Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.通过等位基因特异性PCR快速检测幽门螺杆菌gyrA中赋予对氟喹诺酮耐药性的点突变
J Clin Microbiol. 2007 Feb;45(2):303-5. doi: 10.1128/JCM.01997-06. Epub 2006 Nov 22.
10
Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.日本幽门螺杆菌根除治疗失败后加替沙星耐药性及gyra基因突变情况
Antimicrob Agents Chemother. 2006 Apr;50(4):1538-40. doi: 10.1128/AAC.50.4.1538-1540.2006.
Zotero 插件